Double Standard Over GLP‑1 Drugs Hits Women Especially Hard

When Massachusetts insurers announced they would stop covering GLP‑1 drugs such as Wegovy, the news felt oddly familiar—another case of a life‑saving therapy being labeled “optional” because of cost. What makes this decision especially troubling, however, is how it slams the brakes on progress for women’s health.

Millicent Gorham, the CEO of the Alliance for Women’s Health and Prevention, wrote to the Globe pointing out that the same insurers readily pay for treatments that manage hypertension, diabetes or high cholesterol—conditions that, like obesity, are chronic, costly, and deadly. The difference, she says, lies in the gendered lens through which obesity is viewed.

Obesity isn’t a one‑size‑fits‑all problem. For women, excess weight raises the odds of heart disease, certain cancers, infertility, complications during pregnancy, and even more severe menopause symptoms. Studies have shown that GLP‑1 medications can cut these risks dramatically, yet a policy decision in July 2026 effectively tells women they must bear that burden alone.

The Globe’s own Ideas piece by Carey Goldberg earlier that month highlighted the insurers’ stance: if a drug proves effective, it should be covered. Gorham counters that the logic stops short when the drug in question is a GLP‑1 agonist—a class that, despite solid evidence, remains stigmatized as a “weight‑loss” aid rather than a legitimate therapeutic.

It’s a double standard that hurts. Imagine a woman with a history of hypertension who can easily get her blood‑pressure pills, but can’t obtain Wegovy to lower her BMI and, in turn, reduce her heart‑attack risk. The disparity isn’t abstract; it’s a daily reality for countless patients navigating insurance formularies.

Gorham urges policymakers to apply the same health‑outcome criteria across the board. If insurers can justify covering a statin because it prevents heart attacks, they should just as easily justify covering a GLP‑1 drug that does the same—plus a host of other benefits for women.

The conversation can’t stay stuck on price tags. It has to shift toward equity, outcomes, and the lived experiences of the women who are most affected. Until then, the gap between what science knows and what insurance pays for will keep widening, and women will continue to shoulder the cost of their own health.